Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study
Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study
批准号:
8520948
负责人:
WILLIAM A FRAZIER
金额:
$29.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-17 至 2015-08-31
关键词:
Acute Promyelocytic LeukemiaAdverse effectsAntineoplastic AgentsBindingCD47 geneCell DeathCell Surface ReceptorsCell surfaceCellsClinical TrialsColon CarcinomaComplementCytolysisDataDendritic CellsDetectionDiagnosisEatingFluorescenceGreen Fluorescent ProteinsHematologic NeoplasmsHumanImageImmuneIn VitroKnockout MiceLeukocytesLuciferasesMS4A1 geneMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of prostateMediatingMedicalMembrane PotentialsMitochondriaModelingMonoclonal AntibodiesMusNatural Killer CellsNon-Hodgkin&aposs LymphomaNormal CellPTPNS1 genePatientsPhagocytosisPhasePhosphatidylserinesPublishingQuality of lifeReportingRestSafetySeriesSignal TransductionSolid NeoplasmSurvival RateT-Cell LeukemiaT-LymphocyteTestingTissuesToxic effectTumor BurdenWarXenograft procedurecancer cellcancer therapycell transformationcytotoxiccytotoxicityefficacy testingimprovedin vivoin vivo Modelkillingsleukemiamacrophagemalignant breast neoplasmmouse modelneoplastic cellnew therapeutic targetoutcome forecastpreventprogramspublic health relevancereceptorrituximabtumortumor xenograftuptake
中文摘要
描述(由申请人提供):CD 47已成为血液癌症的新治疗靶点。表达最高水平的CD 47的白血病具有最差的预后。增加的CD 47表达被认为通过经由SIRPa向巨噬细胞发送“不要吃我”信号来保护癌细胞免于吞噬清除,SIRPa是一种抑制性受体,其防止携带CD 47的细胞的吞噬作用。阻断CD 47/SIRPa相互作用的抗CD 47 mAb(CD 47 mAb)可增强癌细胞的吞噬作用,并有助于控制人-小鼠异种移植白血病模型中的肿瘤负荷()。然而,CD 47单克隆抗体可以攻击转化细胞的机制尚未在癌症战争中被利用。 一种特定的抗人CD 47 mAb(克隆1F 7)对人白血病具有直接的细胞毒性作用。MAb 1F 7在没有补体或其他免疫细胞的作用下杀死携带CD 47的肿瘤细胞。相反,mAb 1F 7通过非凋亡机制起作用,该机制涉及对线粒体的直接CD 47依赖性攻击,释放其膜电位(DYm)并破坏细胞的ATP生成能力,导致细胞快速死亡。值得注意的是,mAb 1F 7并不杀死正常的白细胞(也表达CD 47),而只杀死那些通过转化而被“激活”的细胞。因此,正常的循环细胞,所有这些表达CD 47,幸免于难,而癌细胞被肿瘤毒性CD 47 mAb选择性杀死。重要的是,mAb 1F 7还阻断SIRPa与CD 47的结合,因此它可以通过两种机制起作用:(1)直接肿瘤细胞毒性和(2)促进死亡和垂死肿瘤细胞的吞噬作用。我们假设可以实现两种功能的单个mAb将上级仅阻断CD 47/SIRPa结合的mAb。 在这个I期项目中,我们将表征对小鼠白血病细胞具有肿瘤毒性活性的CD 47 mAb,然后测试这些mAb治疗小鼠急性早幼粒细胞白血病(APL)的疗效。在该项目的第二阶段,我们将对候选人CD 47 mAb进行人源化,并评估其有效性和安全性。第一阶段的具体目标是:1。肿瘤毒性CD 47 mAb的鉴定/表征,该mAb选自与来自许多物种(包括小鼠和人)的CD 47反应的一组CD 47 mAb(400系列mAb)。2.将在体内同基因小鼠APL模型中检测目标1中鉴定的肿瘤毒性CD 47 mAb的疗效。APL细胞将用荧光素酶和绿色荧光蛋白(GFP)标记,用于灵敏检测。我们将比较肿瘤毒性CD 47 mAb与简单阻断CD 47/SIRPa结合的CD 47 mAb的抗癌功效。这项研究还将为我们提供这些CD 47 mAb的体内安全性/耐受性的初步指标,这些mAb可以结合白血病和宿主正常细胞上的CD 47,这反映了人类癌症治疗的情况。
英文摘要
DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a "don't eat me" signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing cells. Anti-CD47 mAbs (CD47mAbs) that block the CD47/SIRPa interaction enhance phagocytosis of cancer cells and contribute to control of tumor burden in human to mouse xenograft leukemia models (). However, there are mechanisms by which CD47 mAbs can attack transformed cells that have not yet been exploited in the war on cancer. A particular anti-human CD47mAb (clone 1F7) has a direct, cytotoxic effect on human leukemias. MAb 1F7 kills CD47-bearing tumor cells without the action of complement or other immune cells. Instead, mAb 1F7 acts via a non-apoptotic mechanism that involves a direct CD47-dependent attack on mitochondria, discharging their membrane potential (DYm) and destroying the ATP-generating capacity of the cell leading to rapid cell death. It is noteworthy that mAb 1F7 does not kill normal leukocytes, which also express CD47, but only those cells that are "activated" by transformation. Thus normal circulating cells, all of which express CD47, are spared while cancer cells are selectively killed by the tumor-toxic CD47mAb. Importantly, mAb 1F7 also blocks binding of SIRPa to CD47 and thus it can act via two mechanisms: (1) direct tumor cytotoxicity and (2) promoting phagocytosis of the dead and dying tumor cells. We hypothesize that a single mAb that can accomplish both functions will be superior to one that only blocks CD47/SIRPa binding. In this phase I project, we will characterize CD47mAbs with tumor-toxic activity toward mouse leukemia cells and then test these mAbs for efficacy in treating mouse acute promyelocytic leukemias (APL). In phase II of this program, we will humanize our candidate CD47mAb and evaluate its efficacy and safety. The PHASE I SPECIFIC AIMS are: 1. Identification/characterization of a tumor-toxic CD47mAb selected from a panel of CD47 mAbs (series 400 mAbs) that react with CD47 from many species including mouse and human. 2. Tumor-toxic CD47mAbs identified in Aim 1 will be tested for efficacy in syngeneic mouse APL models in vivo. APL cells will be tagged with luciferase and green fluorescent protein (GFP) for sensitive detection. We will compare anti-cancer efficacy of the tumor-toxic CD47mAbs to a CD47mAb that simply blocks CD47/SIRPa binding. This study will also give us a preliminary indication of in vivo safety/tolerability of these CD47mAbs that can bind CD47 on both the leukemia and the host's normal cells, a situation reflecting human cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.
-
批准号:7669899
-
项目类别:
-
资助金额:$19.77万
-
财政年份:2009
-
负责人:WILLIAM A FRAZIER
-
依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
-
批准号:6752865
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
-
批准号:7418842
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN/CD47 IS A THROMBOSPONDIN RECEPTOR
-
批准号:7622611
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN/CD47 IS A THROMBOSPONDIN RECEPTOR
-
批准号:7370079
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN/CD47 IS A THROMBOSPONDIN RECEPTOR
-
批准号:7883168
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
-
批准号:6547705
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
-
批准号:6607273
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN/CD47 IS A THROMBOSPONDIN RECEPTOR
-
批准号:8100483
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
Integrin Associated Protein in a Thrombospondin Receptor
-
批准号:6901007
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN/CD47 IS A THROMBOSPONDIN RECEPTOR
-
批准号:8288113
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2002
-
负责人:WILLIAM A FRAZIER
-
依托单位:
CD47/IAP Modulation of Immune Cell Functions
-
批准号:6743725
-
项目类别:
-
资助金额:$29.9万
-
财政年份:1998
-
负责人:WILLIAM A FRAZIER
-
依托单位:
CD47/IAP Modulation of Immune Cell Functions
-
批准号:6613293
-
项目类别:
-
资助金额:$31.02万
-
财政年份:1998
-
负责人:WILLIAM A FRAZIER
-
依托单位:
CD47/IAP Modulation of Immune Cell Functions
-
批准号:6888494
-
项目类别:
-
资助金额:$31.05万
-
财政年份:1998
-
负责人:WILLIAM A FRAZIER
-
依托单位:
CD47/IAP Modulation of Immune Cell Functions
-
批准号:6917763
-
项目类别:
-
资助金额:$5.74万
-
财政年份:1998
-
负责人:WILLIAM A FRAZIER
-
依托单位:
CD47/IAP Modulation of Immune Cell Functions
-
批准号:7056817
-
项目类别:
-
资助金额:$29.2万
-
财政年份:1998
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN IS A THROMBOSPONDIN RECEPTOR
-
批准号:2900885
-
项目类别:
-
资助金额:$20.0万
-
财政年份:1997
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN IS A THROMBOSPONDIN RECEPTOR
-
批准号:2685112
-
项目类别:
-
资助金额:$19.44万
-
财政年份:1997
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN IS A THROMBOSPONDIN RECEPTOR
-
批准号:2023399
-
项目类别:
-
资助金额:$19.02万
-
财政年份:1997
-
负责人:WILLIAM A FRAZIER
-
依托单位:
INTEGRIN ASSOCIATED PROTEIN IS A THROMBOSPONDIN RECEPTOR
-
批准号:6181287
-
项目类别:
-
资助金额:$20.59万
-
财政年份:1997
-
负责人:WILLIAM A FRAZIER
-
依托单位:
海外基金